Decreased Fentanyl Potency as the Primary Driver of the 2024 Decline in U.S. Overdose Deaths

BackgroundIn a profound reversal of prior trends, U.S. drug overdose deaths declined by 26.9% in 2024. Two proposed explanations are: (1) expansion of prevention, treatment, and harm-reduction infrastructure and (2) changes in the illicit fentanyl supply. This study evaluated which hypothesis best aligns with observed changes in drug involvement in overdose mortality. MethodsCDC WONDER multiple-cause-of-death data for 2023 and 2024 were analyzed using complementary approaches. In a preliminary analysis, overdose deaths involving cocaine, methamphetamine, prescription opioids, heroin, and methadone were stratified by fentanyl involvement, and 2024/2023 mortality rate ratios were calculated. The primary analysis used a parsimonious 2x2 design (year x fentanyl involvement) to estimate differential mortality changes. A secondary analysis classified deaths into mutually exclusive strata defined by fentanyl, non-fentanyl opioid, and stimulant involvement, and estimated year-by-drug interaction effects using log-linear Poisson regression. ResultsBetween 2023 and 2024, fentanyl-involved deaths declined by 36.5%; non-fentanyl-involved deaths declined by only 5.3% (p < 0.001). Regression models identified a large year x fentanyl interaction (RR = 0.65), consistent with a fentanyl-specific decline. In contrast, non-fentanyl opioid-involved (RR = 1.04) and stimulant-involved deaths (RR = 1.03) exhibited small relative increases. ConclusionsThe 2023-2024 decline in overdose mortality was confined to fentanyl-involved deaths. These findings are most consistent with supply-side changes affecting fentanyl toxicity rather than more uniform effects of infrastructure expansion. Continued investment in prevention and surveillance, with attention to potential market adaptation toward highly potent synthetic opioids, remains essential.